Given that HGF can suppress the risk of cardiovascular disease which is the leading cause of death in NASH patients, exogenous HGF administration may be a favorable option for the treatment of NAFLD. This evidence concerns the gene HGF and metabolic dysfunction-associated steatohepatitis.